After the majority of 21 patients treated in a phase IIa trial showed a significant slow-down of the cancer, Ganymed
has now recruited 210 patients for a phase IIb trial.
Helmut Schmidt, founder and president of GANYMED Computer GmbH, said, "By combining our local presence and experience with NMS' advanced communications products, our customers in Central Europe and Italy will benefit from fast response times, high-quality personal consulting, and the best solutions for today's voice, video, and data communications.
GANYMED Computer GmbH is an embedded distributor and system integrator of high-quality, professional computer, network and communications solutions.
GENEVA, Switzerland, July 11 /PRNewswire-FirstCall/ -- Selexis SA, a Swiss-based biotechnology company offering technologies and services to enable significantly improved drug discovery, development, and cGMP production, announced today that it has signed a commercial license agreement with GANYMED Pharmaceuticals AG, a privately held cancer antibody company of Mainz, Germany, for use of the Selexis technology for large scale production of GANYMED's lead antibodies.
This commercial license agreement allows GANYMED to use a high performance cell line, developed by GANYMED scientists using the Selexis SURE Cell Line Development platform, for the clinical and commercial production of a number of products.
We are thrilled to be extending and possibly intensifying our relationship with GANYMED Pharmaceuticals.
Genmab acquired a license for Ganymed
Pharmaceuticals AG's cancer target GT43.
COPENHAGEN, Denmark, April 26 /PRNewswire/ -- Genmab A/S (CSE: GEN) and privately held Ganymed Pharmaceuticals AG located in Germany, announced today that Genmab will license Ganymed's GT43 cancer target.
Under the terms of the agreement, Ganymed will be entitled to license fees, milestones and royalties on the sale of successfully commercialised products.
Companies contributing included: Antisoma, AstraZeneca, Baxter, Biogen, Boehringer Ingelheim, Celltech, Galileo Pharmaceutical, Ganymed
Pharmaceuticals, GlaxoSmithKline, Hoffman-La Roche, Lundbeck, Novartis, Novo Nordisk, Orion, Pfizer, Proctor & Gamble, and Schering.